Singapore markets closed

Medtronic plc (MDT)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
79.75-0.20 (-0.25%)
At close: 04:00PM EDT
79.65 -0.10 (-0.13%)
After hours: 08:00PM EDT

Medtronic plc

20 On Hatch
Lower Hatch Street
Dublin 2
353 1 438 1700

IndustryMedical Devices
Full-time employees95,000

Key executives

NameTitlePayExercisedYear born
Mr. Geoffrey Straub MarthaChairman of the Board & CEO1.79MN/A1970
Ms. Karen L. ParkhillExecutive VP & CFO992.24kN/A1965
Mr. Sean M. SalmonExecutive VP & President of Cardiovascular Portfolio900.97k418.71k1965
Mr. Robert J. W. ten HoedtExecutive VP & President of Global Regions1.24M96.01k1960
Mr. Mark PloofSenior Vice President of Global Operations and Business ServicesN/AN/AN/A
Ms. Jennifer M. KirkSenior VP, Global Controller & Chief Accounting OfficerN/AN/A1975
Dr. Kenneth E. Washington Ph.D.Senior VP and Chief Technology & Innovation OfficerN/AN/A1960
Dr. Laura Mauri M.D., M.Sc.Senior VP and Chief Scientific & Medical OfficerN/AN/AN/A
Mr. Ryan WeispfenningVP & Head of Investor RelationsN/AN/AN/A
Mr. Ivan K. FongExecutive VP, General Counsel & Secretary985.57kN/A1961
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Corporate governance

Medtronic plc’s ISS governance QualityScore as of 1 June 2024 is 6. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 6; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.